Alzheimer's Biomarkers and Visuospatial Cognition in Parkinson's Disease: Modification by α‐Synuclein and Mediation of Age Effects
Movement Disorders Clinical Practice · 2026-08 · 13 (8) · 1861-1875
DOI: 10.1002/mdc3.70576 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 06.03.2026. Verfasst von David Ledingham und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Ageing Research Unit, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease, Alzheimer Disease, Space Perception. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Background
Visuospatial deficits in Parkinson's disease (PD) often precede dementia and complicate daily functioning. Alzheimer's disease (AD) pathology and α‐synuclein aggregation frequently co‐occur in PD, but their combined impact on cognition is unclear.
Objectives
To examine whether AD biomarker burden relates to visuospatial performance in PD, whether this effect differs by α‐synuclein status, and whether AD biomarkers mediate age‐related decline.
Methods
We analyzed 416 participants from the Parkinson's Progression Markers Initiative. AD biomarker burden was indexed by the cerebrospinal fluid pTau181/Aβ42 ratio; α‐synuclein aggregation was assessed using seed amplification assay. Models adjusted for age, sex, education, and motor severity. Sensitivity analyses included genetic stratification and subgroup exclusion.
Results
Higher AD biomarker burden was associated with poorer visuospatial performance and delayed recall. In participants with concurrent biomarker data ( n = 246), AD burden interacted with α‐synuclein status to predict worse visuospatial outcomes, with the greatest impairment observed in individual's positive for both biomarkers. Mediation analysis indicated that AD biomarker burden accounts for approximately 10–14% of the age effect on visuospatial performance.
Conclusions
AD and α‐synuclein biomarkers show associations consistent with synergistic effects on visuospatial cognition in PD. These findings are exploratory and require replication in pre‐specified independent cohorts. However, if validated, testing both biomarkers could help identify individuals at higher risk of early visuospatial decline and inform hypothesis‐driven stratification in future clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Ageing Research Unit, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, UK.
- Neurosciences, Newcastle Upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK.
- Translational and Clinical Research Institute, The Medical School, Newcastle University, Newcastle upon Tyne, UK.
- Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark.
ORCID-Profile: David Ledingham, Nicola Pavese
Zitieren
APA
Ledingham, D., Sathyanarayana, S., Stewart, C. B., Iredale, R., Foster, V., Galley, D., Lad, M., Baker, M. R., & Pavese, N. (2026). Alzheimer's Biomarkers and Visuospatial Cognition in Parkinson's Disease: Modification by α‐Synuclein and Mediation of Age Effects. Movement Disorders Clinical Practice, 13(8), 1861-1875. https://doi.org/10.1002/mdc3.70576
Vancouver
Ledingham D, Sathyanarayana S, Stewart CB, Iredale R, Foster V, Galley D, et al. Alzheimer's Biomarkers and Visuospatial Cognition in Parkinson's Disease: Modification by α‐Synuclein and Mediation of Age Effects. Movement Disorders Clinical Practice. 2026;13(8):1861-1875. doi:10.1002/mdc3.70576
BibTeX
@article{Ledingham2026,
author = {Ledingham, David and Sathyanarayana, Sahana and Stewart, Charlotte B and Iredale, Robyn and Foster, Victoria and Galley, Debra and Lad, Meher and Baker, Mark R and Pavese, Nicola},
title = {Alzheimer's Biomarkers and Visuospatial Cognition in Parkinson's Disease: Modification by α‐Synuclein and Mediation of Age Effects},
journal = {Movement Disorders Clinical Practice},
year = {2026},
volume = {13},
number = {8},
pages = {1861--1875},
doi = {10.1002/mdc3.70576}
}
EUVIMED